NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 882.6 DKK | +3.66% |
|
-2.22% | +26.43% |
| 05-07 | Novo Nordisk Seeks More Time to Address US Sen. Bernie Sanders' Questions on Drug Pricing | MT |
| 05-07 | Moody’s Revises Novo Nordisk Outlook, Affirms Ratings on Robust Earnings Growth | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
882.6
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.43% | 546B | |
| +33.43% | 690B | |
| -5.12% | 358B | |
| +19.59% | 323B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B | |
| -3.54% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk to Buy Cardior Pharmaceuticals in EUR1 Billion Deal